FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
60.067,77 +1.972,84 (+3,40%)
Repligen Corporation (RGEN)
Dopo ore:
| Chiusura precedente | 157,06 |
| Aperto | 157,63 |
| Denaro | 156,99 x 200 |
| Lettera | 157,27 x 100 |
| Min-Max giorno | 156,33 - 159,41 |
| Intervallo di 52 settimane | 110,45 - 211,13 |
| Volume | |
| Media Volume | 525.612 |
| Capitalizzazione | 8,774B |
| Beta (5 anni mensile) | 1,01 |
| Rapporto PE (ttm) | 212,35 |
| EPS (ttm) | 0,74 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 204,62 |
GlobeNewswireRepligen Appoints Olivier Loeillot as President and Chief Commercial Officer
Olivier Loeillot President and Chief Commercial Officer WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences
GlobeNewswireRepligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applicationsExpands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Meteno
- GlobeNewswire
Repligen Appoints Jason K. Garland as Chief Financial Officer
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer (“CFO”), effective September 25, 2023. Mr. Garland is joining Repligen from his most recent role with medical device outsource (MDO) manufacturer Integer Holdings Corporation (“Integer”), where he served for nearly five years (2018-2023) as Executive Vice Pre
